Merck expands Peenya facility in Bengaluru

IMT News Desk
IMT News Desk
· 1 min read
Tony Qiu, Head of APAC Region, Global Plant Operations, ISCO, Merck Life Science; Prasanna NK, Site Director- Peenya, Bengaluru, Merck Life Science; Aditya Sharma, Head of Process Solutions, India Region, Merck Life Science; and Dhananjay Singh, Managing Director, Merck Life Science

The expansion will transform Peenya into a key manufacturing hub for the APAC region

Merck Life Science in India has announced the expansion of its manufacturing facility in Peenya, Bengaluru, marking a significant milestone in its strategy. The expansion will transform Peenya into a key manufacturing hub for the APAC region, strengthening Merck’s capabilities in production and supporting the growing needs of its customers worldwide.

Merck hosted an inaugural ceremony at the Peenya site, bringing together company leadership, customers and key stakeholders.

Senior leaders including, Tony Qiu, Head of APAC Region, Global Plant Operations, ISCO, Merck Life Science; Prasanna NK, Site Director- Peenya, Bengaluru, Merck Life Science; Aditya Sharma, Head of Process Solutions, India Region, Merck Life Science; and Dhananjay Singh, Managing Director of Merck Life Science, shared insights on the expansion project and emphasised the importance of building sustainable capabilities in Asia and India for future growth.

Read Next

India successfully validates the first indigenous HPV test for Cervical Cancer screening
News
June 13, 2026

India successfully validates the first indigenous HPV test for Cervical Cancer screening

India has achieved a significant milestone in cervical cancer prevention with the successful validation of the country’s first indigenous HPV DNA tests, which meet international standards for cervical cancer screening. Published in the International Journal of Cancer, a multicentre study involving leading Indian and international institutions found that Molbio Diagnostics Truenat HPV-HR Plus met the […]
Article by: IMT News Desk
Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk